Does a plasma level of chlorpromazine help?

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Chemistry

Background:

• Schizophrenia is a complex psychiatric disorder.
• Chlorpromazine (CPZ) is a widely used antipsychotic medication.
• Understanding CPZ pharmacokinetics is crucial for effective treatment.

Purpose of the Study:

• To investigate the relationship between chlorpromazine (CPZ) plasma levels and treatment response in schizophrenic patients.
• To determine if a specific therapeutic window for CPZ plasma levels exists.
• To explore the potential for psychotoxicity at higher CPZ plasma concentrations.

Main Methods:

• Forty-eight newly admitted schizophrenic patients received a fixed dose of CPZ (6.6 mg/kg) for 28 days.
• CPZ plasma levels were quantified using gas chromatography mass spectrometry (GCMS).
• Dosage adjustments were made for non-responders, and outcomes were monitored.

Main Results:

• Initial fixed-dose treatment showed similar CPZ plasma levels in both responders and non-responders.
• Improvement in non-responders occurred across a broad range of CPZ plasma levels (3-72 ng/ml).
• Plasma levels exceeding 95 ng/ml were associated with worsening symptoms (psychotoxicity) in some patients.

Conclusions:

• Treatment response in schizophrenia appears more related to individual illness sensitivity to CPZ than to achieving a specific plasma level.
• CPZ plasma level monitoring may be beneficial for identifying patients at risk of adverse effects, particularly those with limited treatment sensitivity.
• The speed of patient response can complicate the interpretation of plasma levels.